MA55825A - Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation - Google Patents
Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisationInfo
- Publication number
- MA55825A MA55825A MA055825A MA55825A MA55825A MA 55825 A MA55825 A MA 55825A MA 055825 A MA055825 A MA 055825A MA 55825 A MA55825 A MA 55825A MA 55825 A MA55825 A MA 55825A
- Authority
- MA
- Morocco
- Prior art keywords
- vectors
- compositions
- methods
- immunodeficiency virus
- human immunodeficiency
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15200138 | 2015-12-15 | ||
EP16194124 | 2016-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55825A true MA55825A (fr) | 2022-03-09 |
Family
ID=57737697
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47522A MA47522B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
MA055825A MA55825A (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
MA44059A MA44059B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47522A MA47522B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44059A MA44059B1 (fr) | 2015-12-15 | 2016-12-15 | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation |
Country Status (29)
Country | Link |
---|---|
US (3) | US10369214B2 (fr) |
EP (3) | EP3964569A1 (fr) |
JP (2) | JP6510149B2 (fr) |
KR (1) | KR20180086207A (fr) |
CN (2) | CN108368157B (fr) |
AU (2) | AU2016369326B2 (fr) |
BR (1) | BR112018011122A2 (fr) |
CA (1) | CA3008542C (fr) |
CY (2) | CY1122705T1 (fr) |
DK (2) | DK3390430T3 (fr) |
EA (1) | EA038974B1 (fr) |
ES (2) | ES2898271T3 (fr) |
HR (2) | HRP20211566T1 (fr) |
HU (2) | HUE055916T2 (fr) |
IL (1) | IL259942B2 (fr) |
LT (2) | LT3584252T (fr) |
MA (3) | MA47522B1 (fr) |
MD (2) | MD3390430T2 (fr) |
ME (1) | ME03545B (fr) |
MX (2) | MX2018007198A (fr) |
PH (1) | PH12018501047A1 (fr) |
PL (2) | PL3584252T3 (fr) |
PT (1) | PT3390430T (fr) |
RS (2) | RS62360B1 (fr) |
SG (2) | SG11201804411TA (fr) |
SI (2) | SI3390430T1 (fr) |
TW (2) | TWI792091B (fr) |
WO (1) | WO2017102929A1 (fr) |
ZA (1) | ZA201803978B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
EP3031923A1 (fr) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux |
JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
MA49397A (fr) * | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
SG11202000112XA (en) * | 2017-07-19 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
WO2019055888A1 (fr) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Méthodes pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets subissant un traitement antirétroviral |
AR114560A1 (es) * | 2017-11-17 | 2020-09-23 | Grifols Diagnostic Solutions Inc | Proteínas antigénicas de la envoltura del virus de inmunodeficiencia humano expresadas en mamíferos |
WO2020214203A1 (fr) * | 2019-04-17 | 2020-10-22 | The Wistar Institute | Vecteurs adénoviraux à réplication défectueuse pour des applications de type vaccin contre le vih |
WO2020237052A1 (fr) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Procédés pour induire une réponse immunitaire contre une infection par le virus de l'immunodéficience humaine chez des sujets suivant un traitement antirétroviral |
WO2021089770A2 (fr) | 2019-11-07 | 2021-05-14 | Janssen Vaccines & Prevention B.V. | Purification de protéines |
CA3182703A1 (fr) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration de vecteurs adenoviraux homologues |
WO2022006095A2 (fr) * | 2020-06-29 | 2022-01-06 | Duke University | Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc |
WO2022084333A1 (fr) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Régimes de vaccin contre le vih |
CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
WO2023242155A1 (fr) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions et procédés pour le diagnostic d'une infection par le vih |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
CA1341245C (fr) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Virus recombinant de la vaccine derive du virus modifie ankara |
US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
WO1998010087A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Vecteurs d'adenovirus de chimpanze |
US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
DE60043126D1 (de) | 1999-05-17 | 2009-11-19 | Crucell Holland Bv | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
CA2384271A1 (fr) * | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Trimeres stabilises solubles de glycoproteines |
EP1598425A1 (fr) | 2000-11-23 | 2005-11-23 | Bavarian Nordic A/S | Variant modifié du virus de la vaccine ankara |
EP2280074A3 (fr) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations |
CA2785699A1 (fr) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations |
CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
US7285265B2 (en) | 2002-04-25 | 2007-10-23 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
EP2363143A3 (fr) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA exprimant des gènes enveloppe, gag et pol du vih |
US20070166784A1 (en) | 2003-09-15 | 2007-07-19 | Barnett Susan W | Combination approaches for generating immune responses |
US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
EP2567967A3 (fr) * | 2004-04-12 | 2013-08-21 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Méthode pour utiliser les vecteurs adénovirals à mener une réponse immunitaire |
EP1766097A4 (fr) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1 |
AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
US9453239B2 (en) * | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
CA2656741A1 (fr) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur |
AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
CA2655934A1 (fr) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Proteines env vih trimeriques solubles stabilisees et leurs utilisations |
WO2008063331A2 (fr) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci |
WO2008140579A2 (fr) | 2006-11-17 | 2008-11-20 | New York University | Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1 |
AU2008223951B2 (en) | 2007-03-02 | 2014-03-27 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
PT3335728T (pt) | 2008-10-10 | 2020-02-19 | Childrens Medical Center | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
DK2358757T3 (da) * | 2008-11-18 | 2019-01-02 | Beth Israel Deaconess Medical Ct Inc | Antivirale vacciner med forbedret cellulær immunogenicitet |
WO2010085984A1 (fr) | 2009-02-02 | 2010-08-05 | Okairos Ag | Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
WO2010096561A1 (fr) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéines gag du vih/vis de synthèse et leurs utilisations |
WO2011082087A2 (fr) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Protéines de fusion avec des dps destinées à être utilisées dans des vaccins et des produits de diagnostic |
CA2786333C (fr) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Mutants du virus de la vaccine comportant les principales deletions genomiques du virus de la vaccine ankara modifiee |
EP2926830B1 (fr) | 2010-08-31 | 2017-08-02 | Theraclone Sciences, Inc. | Anticorps de neutralisation du virus de l'immunodéficience humaine (vih) |
AU2011343798B2 (en) | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
AP2013007180A0 (en) * | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
WO2013040766A1 (fr) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | Procédé et vaccin pouvant induire une réponse immunitaire à large spectre contre le vih |
WO2013055908A1 (fr) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | Mini boucle v3 de gp120 du vih-1 et ses utilisations |
WO2014047261A1 (fr) | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Virus associés à l'immunodéficience et l'entéropathie et procédés d'utilisation de ceux-ci |
CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
WO2014124301A1 (fr) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Nanostructures protéiques à auto-assemblage |
US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
US10716845B2 (en) * | 2013-10-04 | 2020-07-21 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same |
CA2941116A1 (fr) * | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Vecteurs adenoviaux recombines se repliquant, compositions et procedes pour les utiliser |
EP3189067B1 (fr) | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Protéines de l'enveloppe du vih-1 et leur utilisation |
ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
LT3271729T (lt) * | 2015-03-18 | 2021-02-25 | Janssen Vaccines & Prevention B.V. | Rekombinantinių raiškos sistemų analizės būdai |
JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 CA CA3008542A patent/CA3008542C/fr active Active
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/fr unknown
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/fr not_active Withdrawn
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh active
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 MX MX2018007198A patent/MX2018007198A/es unknown
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/fr active Application Filing
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/fr active Active
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/ko not_active Application Discontinuation
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/fr active Active
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja active Active
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-10-21 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55825A (fr) | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation | |
MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA44077A (fr) | Anticorps neutralisants le virus de l'immunodéficience humaine | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA41558A (fr) | Compositions d'allergènes mélangés et leurs procédés d'utilisation | |
MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
DK3442600T3 (da) | ADENOASSOCIERET VIRUSVEKTORFREMFØRING AF ß-SARCOGLYCAN OG MIKRORNA-29 OG BEHANDLING AF MUSKELDYSTROFI | |
MA50403A (fr) | Promédicaments de dantrolène et leurs procédés d'utilisation | |
MA45982A (fr) | Compositions de neurostéroïdes et leurs procédés d'utilisation | |
MA54148A (fr) | Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation |